These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

97 related articles for article (PubMed ID: 9384335)

  • 1. Viral phenotype, antiretroviral resistance and clinical evolution in human immunodeficiency virus-infected children.
    Mellado MJ; Cilleruelo MJ; Ortiz M; Villota J; García M; Perez-Jurado ML; Barreiro G; Martín-Fontelos P; Bernal A
    Pediatr Infect Dis J; 1997 Nov; 16(11):1032-7. PubMed ID: 9384335
    [TBL] [Abstract][Full Text] [Related]  

  • 2. HIV-1 syncytium-inducing phenotype, virus burden, codon 215 reverse transcriptase mutation and CD4 cell decline in zidovudine-treated patients.
    Kozal MJ; Shafer RW; Winters MA; Katzenstein DA; Aguiniga E; Halpern J; Merigan TC
    J Acquir Immune Defic Syndr (1988); 1994 Aug; 7(8):832-8. PubMed ID: 7517448
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Mutations linked to drug resistance, human immunodeficiency virus type 1 biologic phenotype and their association with disease progression in children receiving nucleoside reverse transcriptase inhibitors.
    Englund JA; Raskino C; Vavro C; Palumbo P; Ross LL; McKinney R; Nikolic-Djokic D; Colgrove RC; Baker CJ;
    Pediatr Infect Dis J; 2004 Jan; 23(1):15-22. PubMed ID: 14743040
    [TBL] [Abstract][Full Text] [Related]  

  • 4. HIV-1 biological phenotype and the development of zidovudine resistance in relation to disease progression in asymptomatic individuals during treatment.
    Boucher CA; Lange JM; Miedema FF; Weverling GJ; Koot M; Mulder JW; Goudsmit J; Kellam P; Larder BA; Tersmette M
    AIDS; 1992 Nov; 6(11):1259-64. PubMed ID: 1282015
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Viral load, viral phenotype modification, zidovudine susceptibility and reverse transcriptase mutations during the first 6 months of zidovudine monotherapy in HIV-1-infected people.
    Rusconi S; De Pasquale MP; Mainini F; Bulgheroni E; Kurtagic S; Gori A; Violin M; Zanchetta N; Moroni M; Balotta C; Galli M
    Antivir Ther; 1996 Dec; 1(4):211-9. PubMed ID: 11324823
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Zidovudine resistance, syncytium-inducing phenotype, and HIV disease progression in a case-control study. The VA Cooperative Study Group.
    St Clair MH; Hartigan PM; Andrews JC; Vavro CL; Simberkoff MS; Hamilton JD
    J Acquir Immune Defic Syndr (1988); 1993 Aug; 6(8):891-7. PubMed ID: 8315574
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Development of resistance of zidovudine (ZDV) and didanosine (ddI) in HIV from patients in ZDV, ddI and alternating ZDV/ddI therapy.
    Nielsen C; Bruun L; Mathiesen LR; Pedersen C; Gerstoft J
    AIDS; 1996 Jun; 10(6):625-33. PubMed ID: 8780817
    [TBL] [Abstract][Full Text] [Related]  

  • 8. HIV-1 viraemia changes in patients with and without syncytium-inducing phenotype treated with nucleoside analogues: a case-control study.
    Leal M; Torres Y; Medrano FJ; Rey C; Caruz A; Sánchez-Quijano A; Lissen E
    Eur J Clin Invest; 1996 Oct; 26(10):923-8. PubMed ID: 8911867
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Diminished selection for thymidine-analog mutations associated with the presence of M184V in Ethiopian children infected with HIV subtype C receiving lamivudine-containing therapy.
    Averbuch D; Schapiro JM; Lanier ER; Gradstein S; Gottesman G; Kedem E; Einhorn M; Grisaru-Soen G; Ofir M; Engelhard D; Grossman Z
    Pediatr Infect Dis J; 2006 Nov; 25(11):1049-56. PubMed ID: 17072129
    [TBL] [Abstract][Full Text] [Related]  

  • 10. HIV-1 viral load, phenotype, and resistance in a subset of drug-naive participants from the Delta trial. The National Virology Groups. Delta Virology Working Group and Coordinating Committee.
    Brun-Vézinet F; Boucher C; Loveday C; Descamps D; Fauveau V; Izopet J; Jeffries D; Kaye S; Krzyanowski C; Nunn A; Schuurman R; Seigneurin JM; Tamalet C; Tedder R; Weber J; Weverling GJ
    Lancet; 1997 Oct; 350(9083):983-90. PubMed ID: 9329513
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Efficient inhibition of both syncytium-inducing and non-syncytium-inducing wild-type HIV-1 by lamivudine in vivo.
    van 't Wout AB; Ran LJ; Nijhuis M; Tijnagel JM; de Groot T; van Leeuwen R; Boucher CA; Schuitemaker H; Schuurman R
    AIDS; 1998 Jul; 12(10):1169-76. PubMed ID: 9677166
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Viral phenotype affects the thymic production of new T cells in HIV-1-infected children.
    Correa R; Muñoz-Fernández MA
    AIDS; 2001 Oct; 15(15):1959-63. PubMed ID: 11600823
    [TBL] [Abstract][Full Text] [Related]  

  • 13. HIV phenotype switching during antiretroviral therapy: emergence of saquinavir-resistant strains with less cytopathogenicity.
    Ercoli L; Sarmati L; Nicastri E; Giannini G; Galluzzo C; Vella S; Andreoni M
    AIDS; 1997 Aug; 11(10):1211-7. PubMed ID: 9256938
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Evaluation of human immunodeficiency virus (HIV) type 1 RNA levels in cerebrospinal fluid and viral resistance to zidovudine in children with HIV encephalopathy.
    Sei S; Stewart SK; Farley M; Mueller BU; Lane JR; Robb ML; Brouwers P; Pizzo PA
    J Infect Dis; 1996 Dec; 174(6):1200-6. PubMed ID: 8940209
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Human immunodeficiency virus type 1 phenotypes in children with advanced disease treated with long-term zalcitabine.
    Viani RM; Smith IL; Spector SA
    J Infect Dis; 1998 Mar; 177(3):565-70. PubMed ID: 9498433
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effect of antiretroviral combination therapy (zidovudine/didanosine or zidovudine/lamivudine) on quantitative plasma human immunodeficiency virus-ribonucleic acid in children and adolescents infected with human immunodeficiency virus.
    Sölder B; Wintergerst U; Notheis G; Eberle J; Gürtler L; Belohradsky BH
    J Pediatr; 1997 Feb; 130(2):293-9. PubMed ID: 9042135
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Maintenance antiretroviral therapies in HIV-infected subjects with undetectable plasma HIV RNA after triple-drug therapy. AIDS Clinical Trials Group Study 343 Team.
    Havlir DV; Marschner IC; Hirsch MS; Collier AC; Tebas P; Bassett RL; Ioannidis JP; Holohan MK; Leavitt R; Boone G; Richman DD
    N Engl J Med; 1998 Oct; 339(18):1261-8. PubMed ID: 9791141
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Clinical significance of human immunodeficiency virus type 1 phenotypes in infected children.
    Spencer LT; Ogino MT; Dankner WM; Spector SA
    J Infect Dis; 1994 Mar; 169(3):491-5. PubMed ID: 7908924
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Plasma viremia and virus phenotype are correlates of disease progression in vertically human immunodeficiency virus type 1-infected children.
    Balotta C; Colombo MC; Colucci G; Viganò A; Riva C; Papagno L; Violin M; Crupi L; Bricalli D; Salvaggio A; Moroni M; Principi N; Galli M
    Pediatr Infect Dis J; 1997 Feb; 16(2):205-11. PubMed ID: 9041602
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Short-term evolution of HIV-1 viraemia and CD4+ cell counts in patients who have a primary mutation to zidovudine.
    Rubio A; Leal M; Rey C; Pineda JA; Sanchez-Quijano A; Lissen E
    AIDS; 1998 Mar; 12(4):395-8. PubMed ID: 9520169
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.